Radiopharmaceuticals/Nuclear Medicine MarketPosted by ahila on April 30th, 2018 Global Radiopharmaceuticals (Nuclear Medicine) Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Global Radiopharmaceuticals (Nuclear Medicine) Market Outline: Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals. A sample of this report is available upon request @ Global Radiopharmaceuticals/Nuclear Medicine Market: Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radiotherapeutic and diagnostic procedures across the globe. Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period. To view TOC of this report is available upon request @ Like it? Share it! More by this author |